• As an adjunct to diet to reduce the risk of myocardial infarction (MI), unstable angina, and/or coronary revascularization procedures in patients without symptomaticcoronary heart disease (CHD), but at high risk
• Slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total cholesterol (Total-C) and low-density lipoprotein cholesterol (LDL-C) to target levels
• As an adjunct to diet for the reduction of elevated Total-C, LDL-C, apolipoprotein B (Apo B), and triglyceride (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson types IIa and IIb,)

• Primary hyperlipidemia and mixed dyslipidemia as adjunctive therapy to diet to reduce elevated total-C, LDL-C, apolipoprotein B (ApoB), non-high-density lipoprotein cholesterol (nonHDL-C), and TG levels and to increase HDL-C in adult patients
  • Heterozygous familial hypercholesterolemia (HeFH) as adjunct to diet to reduce Total-C, LDL-C and ApoB in adolescent boys and girls, who are at least one year postmenarche, 10-17 years of age, if after an adequate trial of diet therapy the following findings are present: LDL-C >190 mg/dL or >160 mg/dL and there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors
• Hypertriglyceridemia treatment of patients as adjunctive therapy to diet
• Primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia) treatment of patients as an adjunct to diet
• Homozygous familial hypercholesterolemia as adjunctive therapy to other lipid-lowering treatmenets (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients
• Slow the progression of atherosclerosis as adjunctive therapy to diet in adult patients as part of a treatment strategy to lower total-C and LDL-C
• Risk reduction of MI, stroke, and arterial revascularization procedures in individuals without clinically evident coronary heart disease, but with an increased risk of cardiovascular disease based on:
  • Age ≥ 50 years old in men and age ≥ 60 years old in women
  • High-sensitivity C-reactive protein (hsCRP) ≥ 2 mg/L
  • Presence of at least one additional cardiovascular disease risk factor such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease

• Primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia for the reduction of elevated Total-C, LDL-C, Apo B, TG and nonHDL-C, and to increase HDL-C
• Homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable for the reduction of elevated Total-C and LDL-C

• Primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients

• Failure to achieve National Cholesterol Education Program (NCEP) goals or clinically significant adverse effects to two generic formulary statins (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin)

• Failure to achieve NCEP goals or clinically significant adverse effects to one generic formulary statin (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin)

AND

• For Vytorin 10/80 mg requests, the patient has been taking 80 mg of simvastatin for 12 months or longer

AND

• For Crestor 40 mg requests, failure to achieve NCEP goals on Crestor 20 mg

• Crestor total daily dose exceeding 40 mg
• Titration to or a new start of an 80 mg daily equivalent of simvastatin
• Altoprev with concomitant administration of:
  • Strong cytochrome P450 isoform 3A inhibitors (e.g., ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, telithromycin, HIV Protease inhibitors, boceprevir, telaprevir, nefazodone)
  • Erythromycin
• Vytorin with concomitant administration of:
  • Strong cytochrome P450 isoform 3A4 (CYP3A4) inhibitors (e.g., itraconazole, ketocaonazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone, and cobicistat-containing products)
  • Gemfibrozil, cyclosporine, or danazol.
• Livalo with co-administration with cyclosporine.
• Non-FDA approved indications, which are not listed in the Health Net Approved Indications and Usage Guidelines section, unless there is sufficient documentation of efficacy and safety in the published literature.

• Relative LDL-lowering Efficacy of Statin and Statin-based Therapies: http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm
• Crestor has been shown to reduce LDL cholesterol by 45 to 63% with doses ranging from 5 mg to 40 mg/day.
• In a 6-week study, Crestor 40 mg reduced LDL cholesterol by 62.6% vs. Crestor 20 mg resulted in a LDL cholesterol reduction by 57%.
• Crestor given at 40 mg per day causes proteinuria as high as 10 times that of other statins. Proteinuria appears to be unique to Crestor and is not a statin class effect.
• Simvastatin is metabolized by the cytochrome P450 isoform 3A4. Certain drugs that inhibit this metabolic pathway can raise the plasma levels of the simvastatin component of Vytorin and may increase the risk of myopathy.
• Gemfibrozil can cause myopathy when used alone, and the risk of myopathy and rhabdomyolysis is increased by concomitant use with simvastatin. The area under the curve (AUC) and peak concentration (Cmax) of simvastatin are increased with concomitant gemfibrozil use.
• Due to the increased risk of myopathy, including rhabdomyolysis, associated with the 10/80 mg dose of Vytorin, patients unable to achieve their LDL-C goal utilizing the 10/40-mg dose of Vytorin should not be titrated to the 10/80-mg dose, but should be placed on alternative LDL-C-Iowering treatment(s) that provides greater LDL-C lowering.
• Crestor 80 mg can cause rhabdomyolysis in rare cases. There is no significant difference in reported incidences of myopathy or rhabdomyolysis between Crestor 40 mg and the highest commercially available doses of statins in clinical trials.
• Liver function tests are recommended before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g. semiannually) thereafter. Crestor is contraindicated in patients with active liver disease or with unexplained persistent elevations of serum transaminases
• Pravastatin is FDA approved for pediatric patients 8 to 13 years up to 20 mg per day and 14 to 18 years up to 40 mg per day; simvastatin is FDA approved for pediatric patients 10 to 17 years of age up to 40 mg per day; and lovastatin is FDA approved for pediatric patients 10 to 17 years of age up to 40 mg per day.
• Doses of Livalo greater than 4 mg once daily were associated with an increased risk for severe myopathy in pre-marketing clinical studies. Do not exceed 4 mg once daily dosing of Livalo.
• Cyclosporine is a known inhibitor of organic anion transporting polypeptide (OATP). Livalo is taken up into human hepatocytes mainly by OATP1B1. Cyclosporine may theoretically inhibit the uptake of Livalo into hepatocytes resulting in increased serum concentrations of Livalo with a 4.5 and 6.6 fold increase in Livalo AUC and Cmax, respectively.
• The risk of myopathy and rhabdomyolysis is increased by high levels of statin activity in plasma. Simvastatin and lovastatin is metabolized by the cytochrome P450 isoform 3A4. Certain drugs that inhibit this metabolic pathway can raise the plasma levels of simvastatin and may increase the risk of myopathy.